From a therapeutic standpoint, most studies on Arf6 have focused on decreasing aberrantly high Arf6 activity in models of cancer, diabetic retinopathy, sepsis, and neurodegeneration 30,37,58–63. The gene discussed is ARF6; the disease is cancer.